WHY IT MATTERS: The policies shaped by this kind of industry coalition could directly affect what medical cannabis products are available to patients, how they are labeled, and whether insurance or federal programs ever cover them. CLINICAL OVERVIEW: The formation of a cross-border cannabis industry coalition comes at a pivotal moment when federal rescheduling discussions in the United States are creating real regulatory uncertainty for both patients and producers. Industry-led organizations of this kind can play a meaningful role in shaping the evidentiary standards and policy frameworks that ultimately determine how patients access medical cannabis, what labeling and dosing information is required, and how physicians are permitted to recommend it.
Cannabis research: India to start human trials for medicinal marijuana – NewsBytes
WHY IT MATTERS: If India’s human trials produce strong safety and efficacy data, it could accelerate regulatory acceptance of medicinal cannabis across South and Southeast Asia, potentially expanding patient access in regions where options are currently very limited. CLINICAL OVERVIEW: India’s launch of human clinical trials for medicinal cannabis represents a significant regulatory and scientific shift for a country with historically strict drug policies. These trials will generate controlled safety and efficacy data across specific medical conditions, helping to establish evidence-based frameworks for potential therapeutic use.
Op-Ed: Cannabis Policy Needs Pharmacists | Pharmacy Times
WHY IT MATTERS: If pharmacists become part of the cannabis care team, patients would benefit from professional drug interaction checks, standardized dosing advice, and a layer of safety oversight that most dispensaries currently cannot provide. CLINICAL OVERVIEW: The role of pharmacists in cannabis care remains largely absent despite cannabis being one of the most widely used therapeutic agents in the country, creating a significant gap in patient safety, drug interaction screening, and dosing guidance. Integrating pharmacists into cannabis dispensing and oversight could dramatically improve outcomes by ensuring patients receive the same level of professional medication management they expect from every other prescription.
5 Exciting Insights from the MedCan 3 Trial
MedCan 3: A Landmark Study on Medicinal Cannabis for Cancer Symptom Management Read The Study Publication The MedCan 3 study is a highly anticipated clinical trial investigating the potential of...